What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with the FDA and compounded GLP-1s has been complex and evolving, driven by high demand for weight loss and diabetes medications like Ozempic (semaglutide) and Mounjaro (tirzepatide), which led to drug shortages.

Here's a breakdown of what happened and who is operating legally:

What Happened with the FDA and Compounded GLP-1s?

1. Drug Shortages Pave the Way for Compounding: When medications like Ozempic and Wegovy (both semaglutide from Novo Nordisk) and Mounjaro and Zepbound (both tirzepatide from Eli Lilly) went into shortage, federal law allows compounding pharmacies to create versions of these drugs. This is typically done to ensure patients can access essential medications.

2. FDA's Concerns About "Salt Forms": The core of the FDA's concern began when many compounding pharmacies started using semaglutide sodium or semaglutide acetate (salt forms of semaglutide) instead of the actual active pharmaceutical ingredient (API) found in the approved drugs, which is semaglutide base.

   • Why this is an issue: The FDA has stated that these salt forms are not the same as the active ingredient in Ozempic/Wegovy, are not FDA-approved for human use, and have not been proven safe or effective. They cautioned against using these forms due to potential safety risks and unknown efficacy. The same concerns apply to compounded tirzepatide using non-approved salt forms.

3. Warning Letters and Enforcement: The FDA has sent numerous warning letters to compounding pharmacies, "medspas," and online platforms that were:

   • Using unapproved salt forms of semaglutide/tirzepatide.
   • Making unsubstantiated claims about their compounded products being "FDA-approved" (they are not, by definition).
   • Operating without proper licenses or quality controls, raising concerns about sterility and potency.
   • Misleading consumers.

4. Branded Drug Manufacturers' Actions: Novo Nordisk and Eli Lilly have also taken legal action against compounding pharmacies, medspas, and wellness clinics, alleging trademark infringement, false advertising, and concerns about patient safety due to the use of unauthorized and potentially unsafe compounded versions of their drugs.

5. Ongoing Stance: The FDA continues to emphasize that compounded GLP-1s are not FDA-approved and do not undergo the same rigorous safety, efficacy, and quality review as approved medications. They have specifically warned consumers about potential risks associated with these products, including adverse reactions and lack of therapeutic effect.

Who is Still Operating Legally?

Operating legally in the realm of GLP-1s means adhering to strict federal and state regulations.

1. FDA-Approved Branded Medications:

   • Novo Nordisk for Ozempic (semaglutide for diabetes, often prescribed off-label for weight loss) and Wegovy (semaglutide specifically for weight loss).
   • Eli Lilly for Mounjaro (tirzepatide for diabetes, often prescribed off-label for weight loss) and Zepbound (tirzepatide specifically for weight loss).
   • These are prescribed by a licensed healthcare professional and dispensed by a licensed retail pharmacy (e.g., CVS Pharmacy, Walgreens, Walmart Pharmacy, Kroger Pharmacy, local independent pharmacies). This is the safest and most regulated route.

2. Legitimate Compounding Pharmacies (with strict caveats):

   • 503A Compounding Pharmacies: These are traditional pharmacies licensed by state boards of pharmacy. They can legally compound drugs only if the FDA-approved version is on the official "drug shortage list," and only for specific patients based on a valid prescription from a licensed healthcare provider.
     • Crucially: They must use the active pharmaceutical ingredient (API) that is identical to the FDA-approved drug (e.g., semaglutide base, tirzepatide base), and not unapproved salt forms like semaglutide sodium or acetate.
     • They must adhere to USP (United States Pharmacopeia) standards for quality and sterility.
   • 503B Outsourcing Facilities: These are larger compounding facilities that are registered with the FDA and operate under stricter cGMP (current Good Manufacturing Practice) standards. They can prepare larger batches of compounded drugs for healthcare facilities (like hospitals or clinics) to dispense.
     • Similar to 503A, they can only compound drugs on the shortage list and must use the appropriate, approved API (semaglutide base, tirzepatide base).

How to identify potentially legal compounding:

• Your doctor's involvement: A legitimate compounded prescription will always originate from a thorough medical consultation with a licensed doctor who determines a medical necessity.
• The specific ingredient: The pharmacy should explicitly state they are using "semaglutide base" or "tirzepatide base," NOT "semaglutide sodium" or "semaglutide acetate."
• Pharmacy verification: Verify the compounding pharmacy is licensed by your state's Board of Pharmacy and adheres to USP standards.
• Drug shortage status: The ability to legally compound these drugs is directly tied to their status on the FDA's drug shortage list. If the shortage resolves, compounding generally becomes illegal.

What to AVOID (likely operating illegally or unsafely):

• Online clinics or "medspas" offering compounded GLP-1s without a thorough medical evaluation or that send you a product without clear pharmacy information.
• Any provider or pharmacy claiming their compounded GLP-1 is "FDA-approved."
• Products advertised as "semaglutide sodium" or "semaglutide acetate."
• Prices that seem too good to be true, as quality ingredients and sterile compounding are expensive.

In summary: The safest and most legally sound way to obtain GLP-1 medications is through a prescription from a licensed healthcare provider for one of the FDA-approved brand-name drugs (Ozempic, Wegovy, Mounjaro, Zepbound) dispensed by a licensed retail pharmacy. If considering a compounded version, ensure it's prescribed by a doctor, dispensed by a legitimate 503A or 503B facility using the correct API (semaglutide base/tirzepatide base), and only when the approved drug is on the FDA's shortage list. Always prioritize your health and consult with your doctor.